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Abstract
Background: In 1999, large-cell neuroendocrine carcinoma of the lung was introduced by the
World Health Organization (WHO) as a new tumor entity in the group of non-small cell, epithelial
tumors, a differentiated classification of neuroendocrine tumors of the lung not existing until this
time. Scientific knowledge on prognosis and therapy of these tumors, especially between those with
neuroendocrine morphology only and those showing additional expression of neuroendocrine
markers, is fragmentary. In this analysis, we studied the clinical behavior and the prognosis of these
two rare tumor entities.
Patients and Methods: The analysis comprises 12 patients of a total of 2053, who underwent
thoracotomy for non small-cell lung carcinoma between 1997 and 2005 in the Department of
Thoracic Surgery at the University Hospital of Freiburg. Clinical data, pathological examinations as
well as complete follow-up were reviewed from large-cell carcinoma with neuroendocrine
morphology only (n=4) and from large-cell carcinoma expressing neuroendocrine markers (n=8).
Results: The median survival of patients with neuroendocrine morphology was 30 months (11–96
months). In the patient group showing the expression of neuroendocrine markers, the median
survival time was 20 months (2–26 months). Tumor recurrences occurred in the group with
neuroendocrine morphology, without exception, in the form of distant metastases and in the group
with neuroendocrine markers as intrapulmonary metastases.
Conclusion: Large-cell neuroendocrine carcinomas of the lung show aggressive behavior with a
poor prognosis. Expression of neuroendocrine markers markedly reduce tumor-free interval as
well as survival and might influence the site of metastases.
Background
Morphologically and clinically-pathologically, neuroen-
docrine tumors of the lung form a heterogeneous group of
pulmonary carcinomas. According to the classification by
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the World Health Organization (WHO) of 1981, the car-
cinoid and the small-cell carcinoma were categorized
together as neuroendocrine tumors. In 1999, at the rec-
ommendation of the WHO as well as the International
Association for Study of Lung Cancer (IASLC) a distinc-
tion was made in the carcinoids into typical and atypical
carcinoid tumors, the large-cell neuroendocrine carci-
noma of the lung being included as a new tumor entity in
its own right [1]. From a clinical-prognostic point of view,
this tumor group can be categorized as being between the
atypical carcinoid and the small-cell carcinoma, tending
more towards the small-cell carcinoma, however [2-4].
Morphologically, in comparison to these parallels are to
be found, above all, with respect to the incidence of mito-
sis and necrosis. The differentiating feature between the
two tumors in conformity with the names they have been
given indicates the cell size as well as the ratio of the cell
nucleus to the cell plasma. The also newly classified so-
called "combined large-cell neuroendocrine carcinoma"
describes all non-small-cell bronchial carcinomas, which
exhibit neuroendocrine morphological characteristics to
only a limited degree, overall, however, keeping their
non-small-cell basic structure. In the past, for the sake of
simplicity, this group of tumors was categorized together
in the group of so-called mixed tumors. Decisive for the
correct classification as a large-cell carcinoma with neu-
roendocrine differentiation (Large Cell Neuro-Endocrine
Carcinoma or LCNEC) is electron microscopic characteri-
zation or the detection of at least one immunohistochem-
ical marker [5]. On the other hand, tumors characterized
as large-cell neuroendocrine tumors merely on the basis
of morphology, i.e., using light microscopy, can be
described as large-cell carcinomas with neuroendocrine
morphology (LCCNM) [6]. The basis for differentiating
between these two groups of tumors has been provided by
Zacharias and Iyoda [6,7]. Taking this distinction into
account, we studied the prognostic and therapeutic signif-
icance of these large-cell neuroendocrine carcinomas.
Patients and methods
The analysis comprises 12 patients with LCCNM or
LCNEC of a total of 2053 patients, who underwent thora-
cotomy for non-small-cell carcinomas between 1997 and
2005; this represents a percentage of 0.6%. Preoperatively,
computed tomography of the thorax, as well as diagnostic
flexible bronchoscopy were performed in all cases. All
patients underwent curative surgery with systematic lym-
phadenectomy, the tumor stage being classified according
to the UICC classification system.
Histopathologically, hematoxylin-eosin staining as well
as an immunohistochemical examination to differentiate
between LCCNM and LCNEC were conducted on a rou-
tine basis. To do this, antibodies for the markers synapto-
physin, neurone-specific enolase (NSE), CD56 and
chromogranin A were used on formalin-fixed as well as
paraffin-embedded tissue sections.
The analysis took into account age and sex, type of opera-
tion, postoperative stage as well as the long-term course of
the patients. Due to the small number of patients, no for-
mal statistical analysis of the data was carried out.
Results
Pathology
Using routine staining, an adenoid or squamous epithe-
lial differentiation in the group of large-cell carcinomas
was excluded. Only those carcinomas were included in
the study which showed the histomorphologically typical
growth patterns of neuroendocrine tumours such as
spherical cell clusters and rosettiform arrangement of the
tumor cells (Figure 1). Neuroendocrine differentiation
could then accordingly be demonstated or excluded
immunohistochemically (e.g. for NSE: Figure 2). Of 12
patients, in 8 patients at least one neuroendocrine marker
could be determined, these thus being classified as
LCNEC (Table 1).
Clinical data
All patient characteristics are described in detail in Table
2. Twelve patients underwent surgery during the period
from May 1997 to February 2005 in the Department of
Thoracic Surgery at the Freiburg University Clinic ( = 1,
 = 11). The mean age was 65 years (41–80). The exact
diagnosis of a large-cell carcinoma with either neuroendo-
crine morphology or neuroendocrine expression could
not be made preoperatively using bronchoscopy.
Large-cell neuroendocrine carcinoma with formation of typi- cal spherical cell clusters, in which tumor cells are arranged  partly trabecularly, partly in the form of a rosette Figure 1
Large-cell neuroendocrine carcinoma with formation of typi-
cal spherical cell clusters, in which tumor cells are arranged 
partly trabecularly, partly in the form of a rosette. (Magnifica-
tion: 100×, Stain: Hematoxylin-Eosin).World Journal of Surgical Oncology 2006, 4:61 http://www.wjso.com/content/4/1/61
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In 4 cases a right-sided, in 7 cases a left-sided operation
was carried out, and in one case a bifurcation resection in
a centrally located tumor. The tumor stage in the group
with LCCNM was I B in two patients, II B in one patient
and III A in one patient. In the group of patients with
LCNEC, the tumor stage was I A in three cases, I B in two
cases, and II B, III B and IV in one case each. In the group
of patients with LCCNM, a lobectomy was performed in
four cases. In the group of patients with LCNEC, a lobec-
tomy was performed three times, a pneumonectomy twice
due to the central location of the tumor, a segment resec-
tion twice because of inadequate pulmonary function as
well as a bifurcation resection in a centrally located carina
carcinoma. A systematic lymphadenectomy was per-
formed in all patients. Adjuvant chemotherapy was given
to patients in tumor stage II a, and more advanced stages.
The median follow-up was 20 months (2–96 months).
The median survival time in the group of patients with
LCCNM was 30 months (11–96 months), one patient still
being alive. In the group of patients with LCNEC, the
median survival time was 20 months (2–26 months), 4
patients still being alive. The 1-year survival rate (1-YSR)
in the group with LCCNM was 40% and in the group with
LCNEC 50%. The median tumor-free survival time in the
group of patients with LCCNM was 41 months (7–96
months), in the group of patients with LCNEC 12 months
(6–24 months). At the time of evaluation one patient in
the group of patients with LCCNM was still alive without
recurrence in a good general state of health, 3 patients
died as a result of intrapulmonary metastases. In the
group of patients with an LCNEC, 4 patients are still alive
without recurrence in a good general state of health and 4
patients died as a result of distant metastases. Tumor
recurrences occurred in the group with LCCNM, without
exception, as intrapulmonary metastases and in the group
with LCNEC in the form of non-pulmonary distant metas-
tases exclusively.
Discussion
In the WHO version of 1981, the carcinoid and the small-
cell carcinoma only were categorized under the term neu-
roendocrine tumors. In 1985, Carter called for a more pre-
cise differentiation of neuroendocrine tumors of the lung
[8]; in an elaborate immunohistochemical analysis of
non-small-cell carcinomas, Linnoila identified several
neuroendocrine markers, especially in large-cell tumors
[9]. In a study based on this, Travis introduced the term
large-cell neuroendocrine carcinoma (LCNEC) as a vari-
ant of the large-cell carcinoma and suggested this tumor
be considered a new tumor entity in addition to the carci-
noid as well as the small-cell carcinoma. This was charac-
terized by light-microscopically determined
phenotypically large, polygonal cells, a high incidence of
mitoses and necroses, as well as the immunohistochemi-
cal or electron microscopic determination of neuroendo-
crine markers [5]. Due to the absence of a consensus as
well as the call for reproducibility and clinical significance
[10], in 1999 the WHO along with the IASLC 1999
included the large-cell neuroendocrine bronchial carci-
noma as a variant of the large-cell carcinoma into the clas-
sification system [1]. Subsequently, on the basis of clearly
defined criteria, an increasing number of clinical series




Synaptophysin - 71 %
NSE - 57 %
CD56 - 43 %
Chromogranin A - 14 %
NSE = Neuron-Specific Enolase.
Immunohistochemical staining for neurone-specific enolase  (NSE) of a large-cell carcinoma with neuroendocrine mor- phology (A) and a large-cell neuroendocrine carcinoma (B) Figure 2
Immunohistochemical staining for neurone-specific enolase 
(NSE) of a large-cell carcinoma with neuroendocrine mor-
phology (A) and a large-cell neuroendocrine carcinoma (B). 
(Magnification: 100×, Stain: NSE).
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were published giving consideration to this new type of
tumor [11-14].
Based on our series of 12 patients, we studied the signifi-
cance of neuroendocrine expression by considering a fur-
ther difference between large-cell bronchial carcinomas
with neuroendocrine morphology only (LCCNM) as well
as large-cell bronchial carcinomas showing the expression
neuroendocrine markers (LCNEC). These tumor groups
differ only in the expression of neuroendocrine markers,
the morphology determined using a light microscope, on
the other hand, being identical in both tumors. Both
groups show growth patterns that are generally typical for
neuroendocrine tumors, independent of their site of ori-
gin. Thus, tumor cell rosettes and clearly delimited spher-
ical cell clusters are found on a regular basis.
This subtyping is not made in the criteria formulated in
1999 by the WHO and IASLC; using a careful division into
these two types of tumor, Zacharias and Iyoda, however,
show that this stratification is of importance with respect
to prognosis and therapy [6,7]. In both the uni-as well as
in the multivariate analysis, Iyoda was able to demon-
strate a worse overall as well as tumor-free survival time in
patients showing the expression of neuroendocrine mark-
ers [7]. Travis demonstrated a relationship between
increased CEA in the serum and shorter survival times [5].
These observations concur with our results on the tumor-
free intervals, which were almost four times shorter in
patients with LCNEC. In contrast, Harada et al, showed an
improved survival time in such tumors in which more
than 2 neuroendocrine markers could be identified
immunohistochemically [15]. The 1-year survival rate in
the LCCNM group was 40%, in the LCNEC group 50%. In
the largest series published so far on large-cell neuroendo-
crine bronchial carcinomas by Takei [11], the 5-year sur-
vival (YS) in stage I was 67%, in stage IV 0%. In our series,
only 2 patients survived 5 years in a tumor stage I B and II
B, all the other patients died within the first 2 postopera-
tive years. Jiang reports on a stage-dependent 1-YS of
58.8%, which is comparable to our LCNEC 1-YS. The
poor prognosis of this tumor becomes clearer when one
considers the 1-YS of 86.2% in patients with NSCLC
undergoing surgery [16], although the overall poor
median survival cannot solely attributed to the neuroen-
docrine nature of these tumors but also to the advanced
tumor stages of the patients in this series.
The clinically aggressive behavior of the LCNEC was also
demonstrated by Iyoda by a significantly enhanced
expression of Bcl-2. He could observe also a shorter
tumor-free survival times [17].
The exact preoperative diagnosis using a bronchoscopic or
transthoracic biopsy proved unsuccessful in all our cases.
The success of a definitive diagnosis of LCNEC preopera-
tively is also judged to be extremely difficult by other
authors as well [13]. Wiatrowska and Kakinuma report on
reliable data based on cytological material [18,19].
Whether a cytological diagnosis is adequate to determine
a therapy concept remains uncertain.
In the group of patients with LCNEC, we could demon-
strate that one tumor recurrence occurred in the form of a
distant metastasis exclusively, whereas in the group of
patients with an LCCNM there was a regular occurrence of
intrapulmonary metastasis. This observation is not to be
found in any of the clinical series published to date; it is
possible that neuroendocrine markers have an influence
on the metastatic process as well as the site of metastasis.
Due to the small number of patients involved, this trend
is not subject to any statistical analysis.
Table 2: Characteristics of patients with large-cell carcinoma and neuroendocrine marker expression as well as with large-cell 
carcinoma and neuroendocrine morphology only.
Patient M/F Age Stage Resection Follow-up (Months) Postoperative Diagnosis Status
1 M 41 II B LL l 60 LCCNM † intrapulmonary recurrence *
2 M 57 I B LL r 96 LCCNM Disease-free
3 M 76 I B LL l 30 LCCNM † intrapulmonary recurrence *
4 M 74 III A UL r 11 LCCNM † intrapulmonary recurrence *
5 M 61 I A S 4/5 l 18 LCNEC Disease-free
6 M 66 I B Pneumonectomy l 26 LCNEC † distant metastases
7 M 75 I A UL l 24 LCNEC Disease-free
8 M 67 I B LL l 20 LCNEC † brain metastases
9 M 70 II B Pneumonectomy r 12 LCNEC † bone metastases
10 F 58 IV UL l 20 LCNEC † bone metastases
11 M 80 I A S 8 r 19 LCNEC Disease-free
12 M 57 III B Bifurcation 2 LCNEC Disease-free
M = male; F = female; LL = lower lobe; UL = upper lobe; l = left; r = right; S = segment; † = deceased; * = intrapulmonary metastases.World Journal of Surgical Oncology 2006, 4:61 http://www.wjso.com/content/4/1/61
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With respect to its severity, LCCNM and LCNEC are clas-
sified as being between the atypical carcinoid and the
small-cell carcinoma, whereby some authors ascribe these
types of tumors a greater similarity to the small-cell carci-
noma. There are features in common regarding the high
incidence of mitosis and necrosis as well as several pheno-
typic characteristics; small-cell carcinomas can also
express a similar spectrum of endocrine markers. Until
present, LCNEC were treated in a similar way to NSCLC,
incorporating adjuvant chemotherapy in a fixed treatment
regimen, however, remaining up until now not being
taken into account. In light of the small number of cases
in the reported series to date, the advantage of such a form
of chemotherapy must be evaluated as still being uncer-
tain. Whereas in a clinical study in patients with non-
small cell bronchial carcinoma and neuroendocrine dif-
ferentiation, an improved survival time as a result of adju-
vant chemotherapy was not reported [2], Iyoda was able
to demonstrate an improvement of survival time of about
20% in stage I with adjuvant chemotherapy [20]. Until
now there have been no studies on this providing a rand-
omized comparison of the group undergoing surgery with
and without adjuvant chemotherapy.
Another adjuvant therapeutic approach already described
before was taken up again by Caretta in a study on 44 neu-
roendocrine carcinomas, in which he points out the
importance of the octreotide scan [21]. Filosso was able to
demonstrate a significant increase in survival time with
adjuvant octreotide therapy in 55% of scintigraphically
positive patients [22].
Conclusion
The tumor groups LCCNM and LCNEC show aggressive
behavior with a poor prognosis. In spite of the small
number of our series, we observe tendencies: tumors
expressing neuroendocrine markers have a considerably
shorter recurrence-free survival time in comparison to the
group of patients showing neuroendocrine morphology
only. Another remarkable feature is the way of relapse.
Tumor recurrence in the LCNEC group occurred exclu-
sively in the form of distant metastases and in the group
of patients with LCCNM, on the other hand, in the form
of an intrapulmonary metastasis.
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